IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Rhea-AI Summary

IMUNON (Nasdaq: IMNN) will host a Third Quarter 2025 Financial Results and Business Update conference call on Thursday, November 13, 2025 at 11:00 a.m. ET. The company will discuss results for the quarter ended September 30, 2025 and provide an update on its Phase 3 clinical development program for IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.

Dial-in numbers are provided for North America and international participants, a live webcast will be available, and the call will be archived for replay through November 27, 2025 with an audio replay accessible for 90 days.

LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025 to discuss financial results for the third quarter ended September 30, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.

To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Third Quarter 2025 Financial Results Call. A live webcast of the call will also be available here.

The call will be archived for replay until November 27, 2025, and can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International Toll) using replay access code 4592282. An audio replay of the call will also be available here for 90 days.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas^®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine^®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:

Media	Investors
Jenna Urban	Peter Vozzo
CG life	ICR Healthcare
212-253-8881	443-213-0505
jurban@cglife.com	peter.vozzo@icrhealthcare.com

FAQ

When will IMUNON (IMNN) report third quarter 2025 results and host the call?

The call is scheduled for November 13, 2025 at 11:00 a.m. ET to discuss the quarter ended September 30, 2025.

How can investors join the IMUNON (IMNN) November 13, 2025 conference call?

Dial 833-816-1132 (U.S. toll-free) or 412-317-0711 (international) and ask for the IMUNON Third Quarter 2025 Financial Results Call, or join the live webcast.

What clinical program will IMUNON (IMNN) update on the November 13, 2025 call?

Management will provide an update on IMNN-001, the company's DNA-based interleukin-12 (IL-12) immunotherapy in Phase 3 development.

How long will the IMUNON (IMNN) call replay be available and how do I access it?

The call archive will be available through November 27, 2025 via replay numbers or an audio replay accessible for 90 days.

Is there an international dial-in and replay code for the IMUNON (IMNN) Nov 13, 2025 call?

Yes. International dial-in is 412-317-0711; replay international toll is 412-317-0088 using access code 4592282.